Chromocell Therapeutics Corp (CHRO) has provided an update.
Chromocell Therapeutics Corporation has recently entered into financial agreements that have bolstered its financial standing. On July 24, 2024, the company secured $750,000 through a convertible note with an accredited investor, featuring a 6% interest rate and a maturity date of August 24, 2025. This note can be converted into common stock at a set price and comes with certain redemption and conversion rights for both the company and the note holder. Following that, on July 26, 2024, Chromocell established a committed equity financing facility with Tikkun Capital LLC, which could see the company raise up to $30 million through the sale of common stock over the next two years. These strategic financial moves are expected to fuel the company’s clinical and pre-clinical work, highlighting a robust approach to securing funds for future growth.
For a thorough assessment of CHRO stock, go to TipRanks’ Stock Analysis page.
